Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ch may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in one or more scientific publications. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Rosa & Co. LLC, a drug development ... today announced its pleasure to be lead partner for ... Systems Pharmacology (QSP). The conference focuses on uses and ... Logo - ... Rosa,s lead sponsorship is the second of ...
(Date:4/28/2015)... -- Boston Scientific Corporation (NYSE: BSX ) generated ... ended March 31, 2015, compared to the company,s ... $1.800 billion.  This represents 6 percent operational revenue ... flat revenue on a reported basis, all compared ... adjusted earnings per share of $0.21 for the ...
(Date:4/28/2015)... INDIANAPOLIS , April 28, 2015  People with ... receive a heart stent are prescribed an oral antiplatelet (OAP) ... blood clot in their heart stent (stent thrombosis), or even ... that 52 percent of 275 ACS patients who were currently ... they take their prescribed OAP therapy, even though most of ...
Breaking Medicine Technology:Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 2DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 3DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 4DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 5DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 2HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 3HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 4HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 7
(Date:4/28/2015)... April 28, 2015 2015 Market ... is a professional and in-depth research report. The ... application, industry overview, industry chain structure, international market ... covers the global (US, Europe, Japan, Asia) and ... macroeconomic environment & economic situation analysis. The Global ...
(Date:4/28/2015)... biologics safety testing market is growing at a favorable ... of the pharmaceutical and biological industries and an increasing ... number of drug approvals in North American countries has ... drug applications and Health Canada approved 99. In addition, ... pharmaceutical and 1,998 of the biotechnology patents granted in ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 28, 2015 A first-in-human prostate ... Molecular Imaging and Biology showed initial safety, biodistribution, ... fluorine-18 labeled small-molecule PSMA inhibitor. The imaging biomarker ... Baltimore, MD by study co-author, Martin G. Pomper, ... of [18F]DCFPyL demonstrated a number of important findings. ...
(Date:4/28/2015)... 2015 The buyer power score for ... 5, indicating a medium level of buyer power in ... have equal power during negotiations. One factor helping buyer ... a health insurance policy from an insurance carrier (such ... can choose to self-fund their own policy or forgo ...
Breaking Medicine News(10 mins):Health News:Centrifuges Market 2015 Global Research Report 2Health News:Centrifuges Market 2015 Global Research Report 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4
... strain is similar to that seen in 1918, with ... 24 (HealthDay News) -- The 2009 H1N1 "swine flu" ... early in the 20th century, two teams of scientists ... people seemed to be less affected by H1N1 during ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
... , ... Another Group Logic Solution to Their Product Portfolio , ... (PRWEB) March 24, 2010 -- Group Logic, the ... the United Kingdom, Jigsaw Systems, is adding the MassTransit product line to its solution ...
... ... solution will power health information exchange across LSU hospital system for more than 2800 ... ... will be able to access patient information across the 10 rural and metropolitan hospitals ...
... This release is available in Spanish . ... area as the original tumour remains the strongest, independent prognostic ... have been free of disease for a very long time, ... Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, a ...
... - Despite the aches and pains that occur in old ... positive experiences from their past. A new study, reported ... ( http://www.elsevier.com/locate/cortex ), reveals that older adults, ability to remember ... way in which the brain processes emotional content. In ...
Cached Medicine News:Health News:H1N1 Virus Yields Up More Secrets 2Health News:Massachusetts health care reform reviewed as a model for national plan 2Health News:Jigsaw Systems to Deliver Group Logic's MassTransit Solution for Managed File Transfer 2Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 2Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 3Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 4Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Older adults remember the good times 2
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
This pediatric blanket is a smaller version of the full body blanket, providing warmth to smaller patients during recovery....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Medicine Products: